Eurizon Capital SGR S.p.A. Takes Position in Stryker Corporation $SYK

Eurizon Capital SGR S.p.A. acquired a new stake in shares of Stryker Corporation (NYSE:SYK) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 97,632 shares of the medical technology company’s stock, valued at approximately $34,333,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Stryker by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after acquiring an additional 133,892 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after acquiring an additional 69,851 shares during the last quarter. Alliancebernstein L.P. lifted its position in shares of Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Stryker by 2.7% during the 4th quarter. Legal & General Group Plc now owns 2,366,107 shares of the medical technology company’s stock valued at $831,616,000 after acquiring an additional 62,817 shares during the last quarter. Finally, Corient Private Wealth LLC lifted its position in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 0.6%

NYSE SYK opened at $305.73 on Friday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $117.21 billion, a PE ratio of 35.39, a price-to-earnings-growth ratio of 1.92 and a beta of 0.80. The firm’s fifty day simple moving average is $321.82 and its 200-day simple moving average is $348.15.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same period last year, the company posted $2.84 earnings per share. The company’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s dividend payout ratio is 40.74%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SYK. Canaccord Genuity Group reduced their target price on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Weiss Ratings lowered Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. William Blair restated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating and issued a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. Finally, Wells Fargo & Company reduced their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 323,264 shares of company stock valued at $100,659,489 over the last three months. 4.60% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.